Brief: Valbiotis H1 Net Loss Widens To 3.5 Million Euros

Valbiotis SA

30/09/2021 07:58

Sept 30 (Reuters) - Valbiotis SA  ALVAL.PA :
    * REVIEWS ITS ACTIVITIES AND PUBLISHES ITS FINANCIAL REPORT
FOR
THE FIRST HALF OF 2021
    * CASH FLOW OF EUR 25.8 MILLION AS OF JUNE 30, 2021
    * FINANCIAL VISIBILITY UNTIL FIRST HALF OF 2024, EXCLUDING
POTENTIAL ADDITIONAL REVENUES
    * FOR THE FIRST HALF OF 2021, VALBIOTIS GENERATED €748K OF
OPERATING INCOME
    * HAS CONDUCTED A SPECIFIC REVIEW OF ITS LIQUIDITY RISK AND
CONSIDERS THAT IT DOES NOT FACE ANY SHORT-TERM RISK: CASH FLOW
HORIZON IS THEREFORE ESTIMATED AT THE FIRST HALF OF 2024
    * COMPLETION OF THIS RECRUITMENT CONFIRMS THE ANNOUNCED
SCHEDULE
OF THE HEART CLINICAL STUDY, THE RESULTS OF WHICH WILL BE
AVAILABLE IN THE SECOND QUARTER OF 2022
    * TOTUM•448, REDUCTION OF HEPATIC STEATOSIS: A PHASE II
STUDY
SHOULD BE INITIATED IN THE SECOND HALF OF THE YEAR
    * H1 NET LOSS EUR 3.5 MILLION VERSUS EUR 2.9 MILLION YEAR
AGO
    * NEW STUDY CO-DESIGNED BY VALBIOTIS TEAMS, INAF EXPERTS AND
NESTLÉ HEALTH SCIENCE EXPERTS: LAUNCH OF THE STUDY IS PLANNED
FOR THE FOURTH QUARTER OF 2021
    * TOTUM•854, REDUCTION OF BLOOD PRESSURE: LAUNCH OF THREE
CLINICAL
STUDIES THAT COULD LEAD TO COMMERCIALIZATION UP TO 3 YEARS AHEAD
OF THE INITIAL PLAN
    * TOTUM•63, PREDIABETES: OBTAINING OF THE PATENT IN CHINA

Source text for Eikon:  ID:nBw92xf9a 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))